Efficacy and Biomarkers of the Second-line Treatment of Adebelizumab Combined With Irinotecan Liposome in Advanced Small Cell Lung Cancer

NCT07004712 · clinicaltrials.gov ↗

PHASE2

Phase

NOT_YET_RECRUITING

Status

46

Enrollment

OTHER

Sponsor class

Conditions

Small Cell Lung Cancer

Interventions

DRUG: Adebelizumab combined with irinotecan liposome as second-line therapy

Sponsor

Peking University Cancer Hospital & Institute